Skip to main content

Drug Interactions between EndaCof-DH and lasmiditan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

brompheniramine dihydrocodeine

Applies to: EndaCof-DH (brompheniramine / dihydrocodeine / phenylephrine) and EndaCof-DH (brompheniramine / dihydrocodeine / phenylephrine)

Using brompheniramine together with dihydrocodeine may increase side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. Some people, especially the elderly, may also experience impairment in thinking, judgment, and motor coordination. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

brompheniramine lasmiditan

Applies to: EndaCof-DH (brompheniramine / dihydrocodeine / phenylephrine) and lasmiditan

Lasmiditan may cause sedation, dizziness, and impaired driving ability. The risk and/or severity may be increased when combined with alcohol or other medications that can also cause sedation. Let your doctor know prior to receiving lasmiditan if you are currently using alcohol or receiving treatment with brompheniramine, as you may be more likely to experience sedation-related side effects. Tell your healthcare provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out. Your healthcare provider may lower your dose or stop the medication until your symptoms go away. Do not drive, operate machinery, or engage in potentially hazardous activities requiring mental alertness and motor coordination until the sedative effects have gone away and you know how these medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

dihydrocodeine lasmiditan

Applies to: EndaCof-DH (brompheniramine / dihydrocodeine / phenylephrine) and lasmiditan

Lasmiditan may cause sedation, dizziness, and impaired driving ability. The risk and/or severity may be increased when combined with alcohol or other medications that can also cause sedation. Let your doctor know prior to receiving lasmiditan if you are currently using alcohol or receiving treatment with dihydrocodeine, as you may be more likely to experience sedation-related side effects. Tell your healthcare provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out. Your healthcare provider may lower your dose or stop the medication until your symptoms go away. Do not drive, operate machinery, or engage in potentially hazardous activities requiring mental alertness and motor coordination until the sedative effects have gone away and you know how these medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

brompheniramine food

Applies to: EndaCof-DH (brompheniramine / dihydrocodeine / phenylephrine)

Alcohol can increase the nervous system side effects of brompheniramine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with brompheniramine. Do not use more than the recommended dose of brompheniramine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Moderate

phenylephrine food

Applies to: EndaCof-DH (brompheniramine / dihydrocodeine / phenylephrine)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  4. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  5. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
View all 7 references

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.